目的：應用患者自體CIK細胞回輸治療中晚期消化道腫瘤，並將療效進行總結。
Objective: use the back-infusion of patients’ autologous CIK cells in treatment of mid to late stage gastrointestinal tumor, and summarize the therapeutic effect.
方法：用人工或機采的方法采集患者自體單個核細胞，淋巴細胞分離液離心分離誘導，激活，並大量擴增，制備成CIK細胞，靜脈輸註治療中晚期惡性腫瘤患者158例。
Methods: collect patients’ autologous mononuclear cells manually or by machine, then induce, activate and amplify them with lymphocyte separation liquid in centrifugal separation method to prepare the CIK cells, and inject into veins of patients of mid to late stage gastrointestinal tumor. 158 cases of therioma done.
結果：經培養後，CIK細胞擴增較好，達到預期質量標準，回輸治療後5例患者完全緩解，14例患者部分緩解，117例病情穩定，25例進展，生命質量明顯提高，治療總疾病控制率為57.18%。治療過程中除2例患者出現壹過性發熱(體溫大約在37-380C之間)，1例自覺關節疼痛，其它未發現任何不良反應。
Results: after cultivation, the CIK cells is well amplified and achieve the desired quality standards. After back-infusion treatment, 5 patients complete relieved, 14 partial relieved, 117 stabilized, 25 improved, quality of life for all patients improved, with a total disease control rate of 57.18%. Except the 2 cases in which 1 patient with pathergy fever (temperature between about 37-380C) and 1 patient with conscious joint pain in the course of treatment, all the others have no adverse reaction.
結論：CIK治療惡性消化道腫瘤安全可靠，副作用小，療效確切，並能有效改善和提高患者的生存質量和臨床癥狀。
Conclusion: the CIK treatment for malignant gastrointestinal tumors are reliable with confirmed curative effect but little side effect, it effectively improve and enhance the quality of life and the clinical symptoms of patients.
關鍵詞：CIK細胞；生物治療；消化道腫瘤
Keywords: CIK cells; biological treatment; gastrointestinal tumor